A Phase 3 interventional study of Aspirin 150 mg and Placebo in Chronic Hypertension Complicating Pregnancy, Pre-Eclampsia and Intrauterine Growth Restriction, sponsored by Centre Hospitalier Intercommunal Creteil. Recruiting at 20 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Centre Hospitalier Intercommunal Creteil · Phase 3, Interventional, and Treatment
A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg/day started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.
Chronic hypertension affects 1 to 5% of women of childbearing age. According to the literature, about 45% of pregnant women with chronic hypertension will develop complications such as superimposed preeclampsia (PE), placental abruption, Intra Uterine Growth Restriction (IUGR), perinatal death, maternal death, or preterm delivery. To date, there is no curative treatment of vascular complications of chronic hypertension during pregnancy. The only effective treatment, once the complications are established, is usually stopping the pregnancy and delivering the placenta. The preventive treatment of these complications is therefore an important axis in the improvement of maternal and perinatal health.
Due to the very high risk of superimposed PE in chronic hypertensive patients and despite the lack of objective evidence of the effectiveness of low-dose aspirin in the prevention of superimposed PE in this population, the NICE (National Institute for Health and Care Excellence), associated with the Royal College of Gynecology-Obstetrics, recommends since 2010-2011 the use of low-dose aspirin in the prevention of this complication in chronic hypertensive pregnant women; then it was followed by the "U.S. Preventive Services Task Force (USPTF)" in 2014. Recently, the American College of Obstetrics and Gynecology (ACOG) adopted the suggestions of the USPTF and issued the same recommendations in 2018. The French college of obstetric (CNGOF: National College of French Gynecologists and Obstetricians), however, does not recommend the use of low-dose aspirin in pregnant chronic hypertensive women because of insufficient data.
Indeed, although the efficacy of low-dose aspirin is assumed in patients with previous PE, few studies have evaluated its efficacy in patients with chronic hypertension. Moreover, most of the controlled prospective studies using very low doses of aspirin (less than 100 mg) and starting after 20 weeks of gestation do not seem conclusive. For these reasons, the investigators propose to conduct a prospective randomized double-blind placebo-controlled trial to analyze the effectiveness of aspirin dosed at 150 mg and introduced before 20 weeks of gestation in women with chronic hypertension.
The primary endpoint is a maternal and perinatal composite morbidity and mortality including superimposed PE, intrauterine growth restriction, preterm delivery \< 37 weeks of gestation, placental abruption, perinatal death, or maternal death.
The definition of superimposed PE in our study is the appearance of significant proteinuria in a chronic hypertensive pregnant woman.
In a secondary analyze, the statistician will use the new definition of superimposed PE that does not require the mandatory presence of proteinuria but the association of chronic hypertension and the appearance of neurological signs (eclampsia, persistent headache, visual disturbances, severe nausea or vomiting), pulmonary edema, persistent epigastric pain, thrombocytopenia \<100000 platelets/µL, liver enzymes at 2 times normal, renal insufficiency ( serum creatinine ≥ 97 μmol/L or 1.1 mg/dL,) or a doubling of serum creatinine in the absence of chronic renal disease or significant proteinuria after 20 weeks of gestation or postpartum.
Significant proteinuria is defined as greater than 300 mg/24 hours or when the ratio proteinuria/ creatininuria is ≥ 30 mg/mmol (ratio to 0.3 if all are in mg/dL), in a non-proteinuric women with no urinary tract infection.
Exclusion Criteria:
Aspirin 150 mg / day (acetylsalicylic acid) once daily in the evening
Drug: Aspirin 150 mg
Placebo taken in the evening
Drug: Placebo
Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
Also known as: Active arm
Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
Also known as: comparator arm
Composite morbidity-mortality criterion including preeclampsia, intra-uterine growth retardation <10th percentile, placental abruption, Preterm birth < 37 weeks of gestation, Perinatal death, Maternal death
A composite morbidity-mortality criterion that includes the occurrence during pregnancy or postpartum of at least one of the following events: preeclampsia, IUGR \<10th percentile, placental abruption, Preterm birth \< 37 weeks of gestation, Perinatal death (death from 22 weeks of gestation until 28 days after birth), Maternal death
Time frame: 9 months
IUGR (< 10th percentile of birth weight)
Rate of IUGR (\< 10th percentile of birth weight)
Time frame: 9 months
Placental abruption
Rate of placental abruption
Time frame: 9 months
Preterm birth < 37 weeks of gestation
Rate of severe preterm delivery (\< 37 weeks of gestation)
Time frame: 9 months
Maternal death
Rate of severe maternal death
Time frame: 9 months
Severe pre-eclampsia
Rate of severe pre-eclampsia. Concerning the rate of superimposed PE, it will be analyze according the two definition specified in the rational
Time frame: 9 months
Intrauterine growth restriction (IUGR)
Rate of severe IUGR (\< 5th percentile of birth weight)
Time frame: 9 months
Preterm delivery
Rate of severe preterm delivery (\< 34 weeks of gestation)
Time frame: 8 months
Fetal loss
Rate of fetal loss (fetal loss between 10 and 21 weeks of gestation)
Time frame: 5 months
Fetal death
Rate of fetal death (fetal death from 22 weeks of gestation until delivery)
Time frame: 5 months
Neonatal death
Rate of neonatal death (death from birth until 28 days)
Time frame: 9 months
Neonatal morbidity
Neonatal morbidity (stay in a neonatal intensive care unit, assisted ventilation \> 24 hours, hyaline membrane disease, intraventricular hemorrhages stage III or IV)
Time frame: 9 months
Toxicity of aspirin
Potential toxicity of the treatment: major maternal bleeding event (active externalized, intracranial, intra-ocular, retroperitoneal, articular), or minor,
Time frame: 8 months
Adherence
Adherence of treatment (diary) and its relationship with the efficacy of the preventive effect on primary outcome,
Time frame: 8 months
Biological response to the treatment
Response to the treatment by a urine thromboxane assay
Time frame: 4 months
Angiogenic profile
Circulating and urinary angiogenic profile associated with maternal and fetal clinical data: sFLT1 ( Soluble fms-like tyrosine kinase-1)(serum and urine), PlGF ( Placental Growth Factor)(serum and urine)
Time frame: 9 months
Child development
Child psychomotor development and health problems at 2 years of age
Time frame: 2 years
Child development
Child psychomotor development and health problems at 4 years of age
Time frame: 4 years
Subgroups analysis
Rate of the composite morbidity-mortality criterion in 2 subgroups: treatment started before or after 15 SA
Time frame: 9 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Intercommunal Creteil